BMY and JNJ Financials: 2025 Revenue Numbers Declared

AI Summary

For FY 2025, Bristol Myers Squibb (BMY) reported revenue of approximately $48.2 billion, reflecting a slight decline of 0.2% year-over-year, while net income was $7.1 billion, yielding a net margin of 14.6%. In contrast, Johnson & Johnson (JNJ) achieved revenue of about $94.2 billion, marking a 6.0% increase, with a net income of nearly $26.8 billion and a net margin of 28.5%. BMY's debt-to-equity ratio stood at 2.6x, while JNJ's was 0.6x, indicating differing financial leverage. Their performance could influence investor strategies given the contrasting growth potential and stability they provide.